Streetbeat News

CMPS

COMPASS Pathways plc

https://compasspathways.com

Industry

Medical - Care Facilities

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Open

5.15

Mkt cap

345M

Volume

3.6M

High

6.04

P/E Ratio

-2.31

52-wk high

12.75

Low

4.97

Div yield

N/A

52-wk low

4.05

A top federal drug official has expressed significant excitement around the potential of psychedelic medicine, while cautioning that it is not a magical solution. This statement highlights the growing interest and research in the field of psychedelics for medical use.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 3:47 pm

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Compass Pathways (NASDAQ:CMPS), maintaining a $120 price target. This reaffirmation of the company's stock potential underscores a positive outlook on its future performance.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 9:46 am

Kaya Holdings Inc. (OTCQB:KAYS), a Florida-based cannabis company, has been granted a license by the Oregon Health Authority to operate a Psilocybin Service Center named The Sacred Mushroom in Oregon. This center, under its subsidiary Fifth Dimension Therapeutics, Inc., aims to provide psilocybin treatment in a unique setting, expecting to welcome its first guests within the next thirty days. The move is seen as a significant step in the mental health sector, with KAYS aiming to become a leader in psychedelic care delivery. Other companies like Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI), and Cybin (AMEX:CYBN) are developing synthetic psilocybin for treatment-resistant mental health disorders, expected to be administered in centers like The Sacred Mushroom.

Portfolio Pulse from Nina Zdinjak

May 09, 2024 | 1:29 pm

Compass Pathways announced its Q1 cash and cash equivalents totaling $262.9M. The company forecasts Q2 2024 net cash used in operating activities to be between $32M and $38M, with the full-year 2024 projection ranging from $110M to $130M, contingent on receiving the 2023 R&D tax credit in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 10:54 am

Compass Pathways reported a Q1 2024 GAAP EPS of $(0.55), which missed the estimated $(0.48). This indicates a larger loss than anticipated for the company during the first quarter of the year.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 10:53 am

Compass Pathways and Mindful Health Solutions have entered into a research collaboration agreement to develop a scalable and cost-effective delivery model for COMP360 psilocybin treatment. This collaboration is among several others aimed at exploring various delivery approaches for COMP360 in different care settings.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:44 am

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS), indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 2:16 pm

Compass Pathways and Journey Clinical have partnered to develop a scalable and practical delivery and healthcare provider training model for COMP360 psilocybin treatment, aimed at treating resistant depression if approved.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 10:38 am

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS), indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 2:40 pm

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS), indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 2:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.